Author:
Boltia Shereen A.,Mora Mai M.,Ismail Nahla S.,Zaazaa Hala E.
Abstract
AbstractTwo rapid, precise, and sensitive stability-indicating high performance chromatographic methods for the measurement of Teriflunomide in its degradation products’ existence were developed. These were RP-HPLC and HPTLC using UV detector. HPLC separation was accomplished utilizing Thermo BDS hypercil C18 column (250 × 4.6 mm, 5 μm) and acetonitrile: 0.03 M potassium dihydrogen phosphate: triethylamine (50:50:0.1%, by volume) as mobile phase at flow rate of 1mL/min. The separated peaks were detected at 250.0 nm. The densitometric approach was conducted utilizing HPTLC 60 F254 silica gel plates, and a developing system of benzene: ethanol: acetic acid (7.5:1:0.25, by volume) and detection was done at 250.0 nm. The developed approaches were evaluated regarding the International Conference on Harmonization (ICH) instructions. The calibration curves of both techniques were constructed with linearity ranges of (5-100) µg/mL and (2–10) µg /band, for HPLC and densitometric determination, consecutively. Teriflunomide was exposed to base and acid hydrolysis, oxidation using H2O2 and finally, thermal degradation as stated in ICH guidelines. The degradation product structures’ elucidation was achieved through LC-MS.
Publisher
Springer Science and Business Media LLC
Reference19 articles.
1. Nair S, Vanathi M, Ganger A, Tandon R. Ocular graft versus host disease: a review of clinical manifestations, diagnostic approaches and treatment. Open J Ophthalmol. 2016;6(1):20–33.
2. Marriott J, O’Connor P. Emerging therapies in relapsing-remitting multiple sclerosis. Rev Recent Clin Trials. 2010;5(3):179–88.
3. Osiri M, Shea B, Robinson V, Suarez-Almazor M, Strand V, Tugwell P, Wells G. Leflunomide for treating rheumatoid arthritis. Cochrane Database syst rev (Online). 2003;1CD002047. https://doi.org/10.1002/14651858.CD002047.
4. Bruneau JM, Yea CM, Spinella-Jaegle S, Fudali C, Woodward K, Robson PA, Sautès C, Westwood R, Kuo EA, Williamson RA, Ruuth E. Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide. Biochem J. 1998;336(2):299–03.
5. O’Connor PW, Li D, Freedman MS, Bar-Or A, Rice GPA, Confavreux C, Paty DW, Stewart JA. Scheyer R. A phase II study of the safety and efficacy of Teriflunomide in multiple sclerosis with relapses. J Neurol. 2006;66(6):894–900.